Please use this identifier to cite or link to this item:
|Title:||Absorption and pharmacokinetics of green tea catechins in beagles|
|Author:||Mata Bilbao, María de Lourdes|
Andrés Lacueva, Ma. Cristina
Roura Carvajal, Elena
Jáuregui Pallarés, Olga
Escribano Ferrer, Elvira
Lamuela Raventós, Rosa Ma.
|Publisher:||Cambridge University Press|
|Abstract:||The present study evaluates for the first time in dogs, the kinetics of green tea catechins and their metabolic forms in plasma and urine. Ten beagles were administered 173 mg (12·35 mg/kg body weight) of catechins as a green tea extract, in capsules. Blood samples were collected during 24 h after intake and urine samples were collected during the following periods of time: 0-2, 2-6, 6-8 and 8-24 h. Two catechins with a galloyl moiety and three conjugated metabolites were detected in plasma. Most of the detected forms in plasma reached their maximum plasma concentration (Cmax) at around 1 h. Median Cmax for (2)-epigallocatechin-3-gallate (EGCG), (2)-epicatechin-3-gallate (ECG), (2)-epigallocatechin glucuronide (EGCglucuronide), (2)-epicatechin glucuronide (EC-glucuronide), (2)-epicatechin sulphate (EC sulphate) were 0·3 (range 0·1-1·9), 0·1 (range 0-0·4), 0·8 (range 0·2-3·9), 0·2 (range 0·1 1·7) and 1 (range 0·3-3·4) mmol/l, respectively. The areas under the plasma concentration v. time curves (AUC0!24) were 427 (range 102-1185) mmol/l £ min for EGC-glucuronide, 112 (range 53-919) mmol/l £ min for EC-sulphate, 71 (range 26-306) mmol/l £ min for EGCG, 40 (range 12-258) mmol/l £ min for EC-glucuronide and 14 (range 0·1-124) mmol/l £ min for ECG. The values of mean residence time (MRT0!24) were 5 (range 2-16), 2 (range 1-11), 10 (range 2-13), 3 (range 2-16) and 2·4 (range 1-18) h for EGCG, ECG, EGC-glucuronide, EC-glucuronide and EC sulphate, respectively. In urine, catechins were present as conjugated forms, suggesting bile excretion of EGCG and ECG. Green tea catechins are absorbed following an oral administration and EGC-glucuronide is the metabolic form that remains in the organism for a longer period of time, suggesting that this compound could suffer an enterohepatic cycle.|
|Note:||Reproducció del document publicat a: http://dx.doi.org/10.1017/S0007114507898692|
|It is part of:||British Journal of Nutrition, 2008, vol. 100, num. 3, p. 496-502|
|Appears in Collections:||Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)|
Articles publicats en revistes (Nutrició, Ciències de l'Alimentació i Gastronomia)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.